Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod

The latest announcement is out from Annovis Bio ( (ANVS) ).

On February 12, 2026, Annovis Bio said an independent Data and Safety Monitoring Board issued a positive safety recommendation at six months for its pivotal Phase 3 Alzheimer’s trial of buntanetap, allowing the U.S. study to continue without modification. The board found no safety concerns and reported that six-month safety data in Alzheimer’s patients were consistent with those previously seen in Parkinson’s patients, with further safety reviews scheduled at 12 and 18 months.

Management noted that alignment of safety outcomes across the Alzheimer’s and Parkinson’s programs has led regulators to indicate they may consider combined safety data in a future new drug application, potentially streamlining buntanetap’s path to market. The Phase 3 Alzheimer’s trial is currently recruiting and reported to be 40% complete, with the first symptomatic efficacy readout expected in early 2027 and a disease-modifying readout anticipated in early 2028, underscoring a long development runway for investors and patients.

The most recent analyst rating on (ANVS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.

Spark’s Take on ANVS Stock

According to Spark, TipRanks’ AI Analyst, ANVS is a Neutral.

The score is primarily held down by weak financial performance (pre-revenue, ongoing losses and cash burn) and a valuation profile dominated by negative earnings. Technicals are mixed (better longer-term trend but weaker near-term), and the recent $6M equity raise modestly helps funding runway while adding dilution risk.

To see Spark’s full report on ANVS stock, click here.

More about Annovis Bio

Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its lead candidate, buntanetap, is an investigational once-daily oral therapy that targets RNA to inhibit multiple neurotoxic proteins implicated in disease progression, with the goal of halting neurodegeneration and improving cognitive and motor function.

Average Trading Volume: 1,703,333

Technical Sentiment Signal: Strong Sell

Current Market Cap: $63.61M

See more data about ANVS stock on TipRanks’ Stock Analysis page.